Pharmacokinetic drug interaction studies with candesartan cilexetil

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Jonkman, J H G ^a   Van Lier, J J ^a   Van Heiningen, P N M ^a   Lins, R ^b   Sennewald, R ^c   Hogemann A ^d  

^a PRA International USA   (Netherlands)

^b Bio Pharma   (Belgium)

^c L A B   (Germany)

^d Takeda Pharma GmbH   (Germany)

Author keywords

Angiotensin II receptor blocker; Candesartan cilexetil; Drug interaction; Healthy volunteers; Pharmacokinetics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIGOXIN; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; WARFARIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; DRUG INTERACTION; MIDDLE AGED;

ADOLESCENT; ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DIGOXIN; DRUG INTERACTIONS; FEMALE; GLYBURIDE; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; NIFEDIPINE; TETRAZOLES; WARFARIN;

EID: 0030661709     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Ashton WT. Nonpeptide angiotensin II receptor antagonists. Exp Opin Invest Drugs 1994, 3: 1105-1142.
2. Morimoto S, Ogihara T. TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 1994, 12: 153-164.
3. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11: (Suppl 2): S9-S17.
4. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974) and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[[2′(1H-tetrazol- 5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-120.
5. Steinijans VW et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991, 29: 232-228.
6. CPMP Working Party on Efficacy of Medicinal Products: note for guidance: investigation of bioavailability and bioequivalence. III/54/89-EN 1991.